Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Director Buys $3,310,159.49 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, June 9th. The stock was acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49. Following the acquisition, the director directly owned 15,683,034 shares in the company, valued at $108,369,764.94. This trade represents a 3.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.00 per share, with a total value of $721.00.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Trading Up 6.7%

NASDAQ ARTV opened at $8.54 on Friday. The stock has a market capitalization of $211.11 million, a price-to-earnings ratio of -2.41 and a beta of 2.38. Artiva Biotherapeutics, Inc. has a twelve month low of $1.47 and a twelve month high of $14.53. The stock has a 50-day moving average of $8.93 and a 200 day moving average of $6.14.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently bought and sold shares of the company. Citadel Advisors LLC increased its stake in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares in the last quarter. Renaissance Technologies LLC increased its stake in Artiva Biotherapeutics by 46.8% during the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after buying an additional 37,053 shares in the last quarter. Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics during the 4th quarter worth approximately $341,000. Finally, Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. HC Wainwright upped their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Finally, Wedbush boosted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.